50 related articles for article (PubMed ID: 22251176)
1. Statistical considerations in model-based dose finding for binary responses under model uncertainty.
Yan Z; Yang M
Stat Med; 2024 May; 43(12):2472-2485. PubMed ID: 38605556
[TBL] [Abstract][Full Text] [Related]
2. Bayesian designs to account for patient heterogeneity in phase II clinical trials.
Thall PF; Wathen JK
Curr Opin Oncol; 2008 Jul; 20(4):407-11. PubMed ID: 18525336
[TBL] [Abstract][Full Text] [Related]
3. Isotonic design for single-arm biomarker stratified trials.
Li L; Ivanova A
Stat Methods Med Res; 2024 Jun; 33(6):945-952. PubMed ID: 38573793
[TBL] [Abstract][Full Text] [Related]
4. Spatial Two-stage Designs for Phase II Clinical Trials.
Kim S; Wong WK
Comput Stat Data Anal; 2022 May; 169():. PubMed ID: 35058669
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase II selection design with order constrained strata.
Chen Y; Yu M
Biometrics; 2024 Jan; 80(1):. PubMed ID: 38364810
[TBL] [Abstract][Full Text] [Related]
6. Sources of bias for single-arm phase II cancer clinical trials.
Jung SH
Ann Transl Med; 2022 Sep; 10(18):1037. PubMed ID: 36267796
[TBL] [Abstract][Full Text] [Related]
7. Phase II Trials for Heterogeneous Patient Populations with a Time-to-Event Endpoint.
Jung SH
Med Res Arch; 2017 Jul; 5(7):. PubMed ID: 29302620
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance).
Martin P; Jung SH; Pitcher B; Bartlett NL; Blum KA; Shea T; Hsi ED; Ruan J; Smith SE; Leonard JP; Cheson BD
Ann Oncol; 2017 Nov; 28(11):2806-2812. PubMed ID: 28945884
[TBL] [Abstract][Full Text] [Related]
9. Improved two-stage tests for stratified phase II cancer clinical trials.
Chang MN; Shuster JJ; Hou W
Stat Med; 2012 Jul; 31(16):1688-98. PubMed ID: 22422466
[TBL] [Abstract][Full Text] [Related]
10. Optimal and minimax three-stage designs for phase II oncology clinical trials.
Chen K; Shan M
Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
[TBL] [Abstract][Full Text] [Related]
11. Statistical issues for design and analysis of single-arm multi-stage phase II cancer clinical trials.
Jung SH
Contemp Clin Trials; 2015 May; 42():9-17. PubMed ID: 25749311
[TBL] [Abstract][Full Text] [Related]
12. Group-sequential methods for adaptive seamless phase II/III clinical trials.
Stallard N
J Biopharm Stat; 2011 Jul; 21(4):787-801. PubMed ID: 21516569
[TBL] [Abstract][Full Text] [Related]
13. Phase II cancer clinical trials with heterogeneous patient populations.
Jung SH; Chang MN; Kang SJ
J Biopharm Stat; 2012; 22(2):312-28. PubMed ID: 22251176
[TBL] [Abstract][Full Text] [Related]
14. Optimal designs for phase II clinical trials with heterogeneous patient populations.
Liu L; Cao S; Jung SH
J Biopharm Stat; 2023 Jan; 33(1):1-14. PubMed ID: 35793231
[TBL] [Abstract][Full Text] [Related]
15. A modification of Simon's optimal design for phase II trials when the criterion is median sample size.
Hanfelt JJ; Slack RS; Gehan EA
Control Clin Trials; 1999 Dec; 20(6):555-66. PubMed ID: 10588296
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
